ArticleFrontiers in immunology2025
Case Reports: Three cases of autoimmune glial fibrillary acidic protein astrocytosis in disguise.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical characteristics of autoimmune GFAP astrocytopathy with concomitant Epstein-Barr virus positivity: a case series of 12 patients and literature review.Journal of neurology · 2026Review
- Tuberculous meningoencephalitis concurrent with autoimmune glial fibrillary acidic protein astrocytopathy: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune glial fibrillary acidic protein astrocytosis (GFAP-A), a novel inflammatory autoimmune disorder of the central nervous system, manifests with insidious onset and demonstrates protean clinical manifestations, which frequently leads to diagnostic ambiguity in early disease stages. We describe three typical GFAP-A cases exhibiting multisystem neurological involvement. Our observations show that GFAP-A frequently clinically mimics tuberculous meningitis (TBM), autoimmune encephalitis (AE), neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), and other neurological diseases. Notably, isolated ataxia is a rare presentation in GFAP-A, which allows us usually to consider spinocerebellar ataxia (SCA). Currently, no established diagnostic criteria or standard treatment protocols exist for GFAP-A. Patients with GFAP-A respond well to corticosteroid therapy. We found detecting GFAP-IgG in cerebrospinal fluid or serum is essential for differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.